GLP-1 Nutritional Support - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The gLP-1 nutritional support market size is expected to grow from USD 3.45 billion in 2025 to USD 3.88 billion in 2026 and is forecast to reach USD 6.94 billion by 2031 at 12.35% CAGR over 2026-2031. This report is Segmented by Product Type (Protein Blends, Fiber Supplements, Micronutrient Blends, Digestive Health, Appetite/Metabolic Support), Dosage Form (Powders, RTD Shakes, Capsules, Gummies), Age (18-34, 35-54, 55-74, 75+), Channel (Prescription, OTC), Distribution (Online, Pharmacies, Supermarkets), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts in Value (USD).

Global GLP-1 Nutritional Support Market Trends and Insights

Rising GLP-1 Adoption In Weight Management

The GLP-1 nutritional support market is getting its clearest demand lift from the rise in GLP-1 prescribing for weight management. Anti-obesity medication prescribing grew 10.1% from September 2025 to December 2025, and GLP-1 prescriptions moved above 7% of all prescriptions in the United States by December 2025. Medicare Part D gross spending on GLP-1 medicines reached USD 27.5 billion in 2024, which showed how deeply these therapies had already entered mainstream care pathways. That increase matters for the GLP-1 nutritional support market because each new user creates practical needs around muscle retention, lower-volume nutrition, and better tolerance during reduced food intake. As prescription use becomes more routine, the GLP-1 nutritional support market moves closer to a repeat-use wellness category rather than a niche clinical add-on.

Need For Lean-Mass Preservation And Protein Repletion

The GLP-1 nutritional support market is also gaining from clear evidence that weight loss on GLP-1 therapy often includes meaningful lean tissue loss. The 2025 joint advisory reported that 38%-40% of total weight lost during GLP-1 therapy can come from lean body mass, and the STEP 1 semaglutide trial recorded 5.3 kg of lean tissue loss within a 13.6 kg total reduction. Research presented at ENDO 2025 found higher muscle loss risk among older adults, women, and people with lower protein intake, and it also linked greater lean mass loss with less HbA1c improvement. The same advisory set protein targets at 1.2-1.6 g/kg/day and flagged deficiencies in iron, calcium, magnesium, zinc, and several vitamins, which gives the GLP-1 nutritional support market a strong clinical reason to favor targeted protein and micronutrient products. A 2025 study in Diabetes, Metabolic Syndrome and Obesity further supported this direction by linking oral nutritional supplements with improved lean mass preservation, especially among younger adults and longer-duration users.

Gastrointestinal Tolerance Limits Repeat Use

The GLP-1 nutritional support market faces a repeat-use challenge because nausea, constipation, and slowed gastric emptying can make even useful nutrition products harder to tolerate. This issue is shaping formulation choices more than simple flavor or branding decisions because products must stay gentle while still delivering meaningful protein and micronutrient density. Nestlé Health Science addressed that need with whey protein microgel technology in BOOST Advanced, which was designed for adults on a GLP-1 weight loss journey. Danone made a similar adjustment with Oikos Fusion by using a compact 7 fl oz format that reflects the low-volume needs of users with reduced appetite. These responses show that the GLP-1 nutritional support market can grow, but repeat demand will stay weaker for products that feel too heavy, too large, or too hard to digest during active therapy.

Other drivers and restraints analyzed in the detailed report include:

• Clinical Nutrition Protocols Expanding Adjunct Demand
• Oral GLP-1 Expansion Increasing At-Home Nutrition Support Use
• High Cost Of GLP-1 Therapy Constrains Addressable Demand

Segment Analysis

Protein and Macronutrient Blends captured 45.31% of the GLP-1 nutritional support market share in 2025, which kept them well ahead of other product types in the current mix. That position reflects a practical clinical need because the 2025 joint advisory set protein intake at 1.2-1.6 g/kg/day for GLP-1 users, a level many patients will struggle to reach through reduced food intake alone. The leading products in this category are built around concentrated delivery rather than general wellness messaging, which explains why companies are emphasizing large protein loads in compact servings. Nestlé's BOOST Advanced delivers 35 g of protein per serving, Abbott's Ensure Max Protein 42 g exceeds many mainstream thresholds, and these formats fit the clinical direction of the GLP-1 nutritional support market.

Appetite and Metabolic Support is projected to expand at 14.38% CAGR through 2031, which makes it the fastest-growing sub-segment in this product set. Growth is tied to the shift toward self-managed therapy, especially as oral GLP-1 access broadens and users look for more complete support rather than protein alone. Fiber Supplements and Digestive Health Formulations are also moving up because constipation and altered gastric motility are now treated as practical nutrition issues rather than side notes. Micronutrient Blends remain relevant because the joint advisory identified risks around iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, and B12 during GLP-1 therapy. The GLP-1 nutritional support industry is therefore moving toward clinically specific formulations that can address muscle retention, digestive comfort, and nutrient adequacy within one patient journey.

Powders held 39.24% share in 2025, which shows that the GLP-1 nutritional support market still relies heavily on formats with broad distribution, lower cost per serving, and familiar use in pharmacy and clinical settings. Powders also fit prescription-led pathways because they are easy to position inside managed nutrition programs where dosing and protein targets are discussed directly with clinicians. Their shelf stability and formulation flexibility make them useful for protein blends, fiber support, and specialized mixes that need a broader nutrient load. This established base explains why powders remain the largest dosage form even as newer, more convenient options pick up speed.

Ready-to-Drink Shakes are projected to grow at 14.52% CAGR, which makes them the strongest growth pocket within the GLP-1 nutritional support market size outlook for dosage forms. The reason is simple because many users eat less, want fewer steps, and respond well to single-serve products that do not require measuring, mixing, or cleanup. Danone's Oikos Fusion combines 23 g of protein with a compact 7 fl oz serving, and that design matches the low-volume pattern that GLP-1 therapy often creates. Capsules and Tablets remain important for micronutrient delivery, while Gummies and Chews are gaining ground with younger users who prefer alternatives to standard pill formats. Across the GLP-1 nutritional support industry, dosage-form development is now centered on convenience, tolerance, and nutrient density rather than on broad meal replacement logic.

Complete Report Scope:

• By Product Type
  • Protein and Macronutrient Blends
  • Fiber Supplements
  • Micronutrient Blends
  • Digestive Health Formulations
  • Appetite and Metabolic Support
  • Other Product Types
• By Dosage Form
  • Powders
  • Ready-to-Drink Shakes
  • Capsules and Tablets
  • Gummies and Chews
  • Other Dosage Forms
• By Age Group
  • 18 to 34 Years
  • 35 to 54 Years
  • 55 to 74 Years
  • 75 Years and Above
• By Channel
  • Prescription
  • Over-the-Counter
• By Distribution Channel
  • Online Stores
  • Pharmacies
  • Supermarkets
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.22% of the GLP-1 nutritional support market share in 2025, which made it the leading regional cluster in the current landscape. The region benefits from strong GLP-1 penetration in the United States, where prescriptions exceeded 7% of all dispensed prescriptions by December 2025. That prescription base supports the GLP-1 nutritional support market because a larger active user pool creates repeat demand for protein support, digestive support, and micronutrient products. North America also has the deepest concentration of launches from major nutrition companies, including Abbott, Nestlé Health Science, Danone, and The Vitamin Shoppe, which keeps product availability high across both clinical and retail channels. Canada is moving in the same direction as U.S. clinical use expands, while Mexico remains earlier stage because affordability still limits broader uptake. Europe remains the second major area of development, and its regulatory setting favors more carefully substantiated nutrition positioning, which suits clinically framed products better than loose wellness claims.

Asia-Pacific is projected to grow at 16.15% CAGR through 2031, which gives it the fastest regional growth profile in the GLP-1 nutritional support market. The region is gaining momentum because access to GLP-1 therapy is widening in large population markets, and that expands the base for companion nutrition products. India is an important part of this story because rapid drug access expansion is creating room for localized nutrition offerings tied directly to GLP-1 and GIP therapy. Japan adds another layer of growth because its Functional Food Claims system supports formalized positioning for metabolic health products, and Kobayashi Pharmaceutical launched Salacia 100 Premium in March 2026 as the first supplement approved to support normal HbA1c levels in the country. China, South Korea, and Australia also strengthen the regional outlook through urban adoption, established supplement habits, and strong interest in higher-protein nutrition.

South America and the Middle East and Africa remain smaller in current revenue terms, but they still matter to the GLP-1 nutritional support market because obesity prevalence and premium healthcare pockets support long-run demand formation. Brazil stands out in Latin America because supplement companies are already testing GLP-1-specific positioning, including Vitafor's GLP-1 Support Multivitamínico launch in August 2025, even though household use remains concentrated in higher-income groups. The broader population need is visible because PAHO reported that 67.5% of adults in Latin America had excess weight, which leaves a large future base for medication and companion nutrition adoption. In MEA, the GCC offers the clearest entry point because high private healthcare coverage, elevated obesity prevalence, and established premium nutrition distribution create a favorable setting for early category development.

List of Companies Covered in this Report:

• Abbott Laboratories
• ADM
• Bio-Synergy
• Cambridge Nutritional Foods
• Conagra Brands
• Danone
• Glanbia
• Herbalife
• Huel
• Ingredients by Nature
• Keptropy
• KetoZest
• Medifast
• Natnect
• Nestle
• ProCare Health
• Replenza
• Saanroo
• The Vitamin Shoppe
• Unjury Protein
• Vital Nutrients

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support